rybrevant
janssen-cilag international n.v. - amivantamab - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.
cabazitaxel fresenius kabi
fresenius kabi polska sp.z.o.o. - kabazitakselis - koncentratas infuziniam tirpalui - 20 mg/ml - cabazitaxel
cabazitaxel teva
teva b.v. - kabazitakselis - koncentratas infuziniam tirpalui - 10 mg/ml - cabazitaxel
tecvayli
janssen-cilag international n.v. - teclistamab - daugybinė mieloma - antinavikiniai vaistai - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
pedmarqsi
fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - visi kiti gydomieji produktai - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.
cabazitaxel stada
stada arzneimittel ag - kabazitakselis - koncentratas infuziniam tirpalui - 20 mg/ml - cabazitaxel
briumvi
neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresantai - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.
talvey
janssen-cilag international n.v. - talquetamab - daugybinė mieloma - antinavikiniai vaistai - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
xonvea
exeltis baltics, uab - doksilamino-vandenilio sukcinatas/piridoksino hidrochloridas - skrandyje neirios tabletės - 10 mg/10 mg - doxylamine, combinations
xonvea
exeltis baltics, uab - doksilamino-vandenilio sukcinatas/piridoksino hidrochloridas - modifikuoto atpalaidavimo tabletės - 20 mg/20 mg - doxylamine, combinations